Higher fibromyalgia and chronic pain risks followed SARS-CoV-2 infection
An analysis of retrospective cohort studies reported increased risks of fibromyalgia and chronic pain diagnoses after SARS-CoV-2 infection, compared with reference groups not identified in this summary.
The analysis examined 2-year risk trajectories. Without details of those reference populations, the reported relative magnitudes cannot be interpreted here.
See the evidence
Chronic Pain Diagnosis
+54% HR 1.54 (95% CI: 1.42-1.67)
Taquet M, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies. Lancet Psychiatry. 2022;9(10):815-827.
Taquet M, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies. Lancet Psychiatry. 2022;9(10):815-827.
Headache was reported as early and persistent in COVID-19
The study described headache as both an early and persistent symptom in people with COVID-19.
The specific COVID-19 population, follow-up, and named comparator for the relative headache result are not available in this summary, so its magnitude is omitted.
See the evidence
Headache Disorder
+89% HR 1.89 (95% CI: 1.54-2.32)
Caronna E, et al. Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia. 2020;40(13):1410-1421.
Study-specific findings. Different populations, treatments and follow-up periods can produce different results.
THE RESEARCH, AS IT ARRIVES
Latest studies.
The newest findings added to this collection. The learning from each, already distilled.
Study summaries are not available in this collection yet. The original evidence remains accessible in each monitor.
Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.
WHEN YOU WANT TO GO DEEPERSee all 4 findingsOriginal results, comparisons and study details.
3 of 3 source groupsFindings stay together with their study.
SOURCE 062 findings
Taquet M, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies. Lancet Psychiatry. 2022;9(10):815-827.
Caronna E, et al. Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia. 2020;40(13):1410-1421.
Fernandez-de-las-Penas C, et al. Long-COVID symptoms in individuals infected with different SARS-CoV-2 variants: A systematic review. Viruses. 2023;15(3):746.
Alkodaymi MS, et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: A systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(5):657-666.
Taquet M, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies. Lancet Psychiatry. 2022;9(10):815-827.
Novak P, et al. Post COVID-19 syndrome associated with orthostatic cerebral hypoperfusion syndrome, small fiber neuropathy and benefit of immunotherapy. eNeurologicalSci. 2022;26:100388.
Fernandez-de-las-Penas C, et al. Sensitization symptoms are associated with psychological and cognitive variables in COVID-19 survivors. Pain Med. 2023;24(4):400-409.
Caronna E, et al. Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia. 2020;40(13):1410-1421.
Peluso MJ, et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021;36(6):109518.
Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12:698169.
Bonilla H, et al. Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative. Front Immunol. 2023;14:1129459.
Oaklander AL, et al. Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain. 2013;154(11):2310-2316.
Systrom DM, et al. Reduced aerobic capacity in patients with long COVID with normal pulmonary function and peripheral oxygen extraction. Chest. 2021;160(4):A1304-A1305.
Systrom DM, et al. Invasive cardiopulmonary exercise testing reveals abnormal hemodynamics and reduced exercise capacity in patients with long COVID. ERJ Open Res. 2023.
Joseph P, et al. Insights from invasive cardiopulmonary exercise testing of patients with myalgic encephalomyelitis/chronic fatigue syndrome. Chest. 2021;160(2):642-651.
Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology. 2023;21(3):133-146.
This is an AI-assisted evidence summary, not a clinician endorsement. Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results.
Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed. Personal health and treatment decisions belong in a conversation with a qualified clinician.